摘要
目的探究mi R-502-3p通过对脂肪酸结合蛋白7(FABP7)的调节作用抑制肾透明细胞癌(CCRCC)进展的分子机制。方法本研究通过病例对照研究,对100名肾透明细胞癌患者及100名健康对照者FABP7的mi R-502结合位点基因型测序,分析基因型与肾透明细胞癌发病风险之间关系,并通过免疫组织化学法测定不同基因型肾透明细胞癌肿瘤组织FABP7蛋白表达量,分析FABP7基因表达量与mi R-502-3p之间关系,为肾透明细胞癌防治提供参考。结果分析mi R-502有3个基因型:TT、CT和CC,在100例CCRCC患者中,TT、CT、CC基因型频率分别是57.00%、33.00%、10.00%,C、T等位基因频率在CCRCC病人和健康者之间有差异(P<0.05);用CC基因型作对照,并分别与CT、TT及CT+TT基因型作比较,有显着差异(P<0.05)。FABP7与CC基因型无显著差异(P>0.05),FABP7在CT、TT型呈高表达(P<0.05)。结论mi R-502-3p可作为CCRCC患者发病风险的预测因子,可通过mi R-502-3p抑制FABP7的表达,进而家加速CCRCC细胞凋亡,有可能作为肾癌治疗的潜在靶点。
Objective To explore the molecular mechanism of miR-502-3p in inhibiting the progression of renal clear cell carcinoma(CCRCC)through the regulation of fatty acid-binding protein 7(FABP7).Methods In a case-control study,we analyzed miR-502 binding sites in 100 renal clear cell carcinoma and 100 healthy controls,and analyzed FABP7 protein expression relationship between FABP7 gene expression and miR-502-3p to provide a reference for the prevention and treatment of renal clear cell carcinoma.Results The miR-502 has three genotypes:TT,CT and CC.In T,100 CCRCC patients,TT,CT and CC genotypes were 57.00%,33.00% and 10.00%,C and T allele frequencies varied between CCRCC patients and healthy patients(P<0.05);CC genotype was compared with CT,TT and CT+TT genotypes respectively(P<0.05).The FABP7 and the CC genotypes were not significantly different(P>0.05),and the FABP7 was highly expressed in the CT and TT types(P<0.05).Conclusions miR-502-3p can be used as a predictor of the risk of CCRCC patients,can inhibit FABP7 expression through miR-502-3p,and then accelerate the apoptosis of CCRCC cells,and may serve as a potential target for renal cancer treatment.
作者
刘正清
梁冬波
丁红
龙四军
马将糯
曾丽君
LIU Zheng-qing;LIANG Dong-bo;DING Hong;LONG Si-jun;MA Jiang-nuo;ZENG Li-jun(Intensive Care Unit,Suizhou Hospital of Traditional Chinese medicine affiliated to the Hubei University of Chinese Medicine,Suizhou 441300,Hubei Province,China)
出处
《罕少疾病杂志》
2024年第2期71-73,共3页
Journal of Rare and Uncommon Diseases
基金
湖北省随州市卫健委重点项目(2021SZ32005)。
